Nektar Therapeutics Stock News

Upgrades For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 1 0 L

The company is throwing in the towel on its lead pipeline program.

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog

Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Mye

Nektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb's Opdivo.

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. 

Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market tr

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ: NKTR ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Nektar Therapeutics has an average price target of $10.5 with a high of $21.00 and a low of $6.00. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the … Full story available on Benzinga.com